Aastrom Biosciences, Inc.
ASTM, the leading developer of patient-specific, expanded
multicellular therapies for the treatment of severe, chronic cardiovascular
diseases, today announced that Tim M. Mayleben has decided to retire from his
position as the company's president and chief executive officer once the
company has hired his successor. As a result of his decision, the Aastrom
board of directors has initiated a search for a new CEO. In addition to
remaining as president and CEO until a successor is found, Mr. Mayleben will
continue to serve as a member of the board of directors after the transition.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in